From the Research
Nattokinase is a safe and efficient treatment for preventing thrombotic events, as demonstrated by a recent study published in 2021, which showed that nattokinase improved clinical symptoms in patients with vascular diseases without causing adverse drug reactions or interactions 1.
Key Findings
- The study published in 2021 found that nattokinase was able to improve clinical symptoms in patients with vascular diseases, including deep vein thrombosis, phlebitis, and venous insufficiency, without causing adverse drug reactions or interactions 1.
- Another study published in 2019 compared the anti-thrombotic activity and hemorrhagic adverse effects of nattokinase and tissue-type plasminogen activator, and found that nattokinase had a relatively low hemorrhagic risk compared to tissue-type plasminogen activator 2.
- A study published in 2009 found that nattokinase decreased plasma levels of fibrinogen, factor VII, and factor VIII in human subjects, which could help reduce the risk of cardiovascular disease 3.
Safety and Efficacy
- Nattokinase has been shown to be safe and efficient in preventing thrombotic events, with a low risk of hemorrhagic adverse effects 1, 2.
- However, patients with bleeding disorders, upcoming surgery, or who are pregnant or breastfeeding should avoid nattokinase due to the potential risk of bleeding complications.
- Nattokinase may interact with anticoagulant and antiplatelet medications, potentially increasing bleeding risk, and patients should consult their healthcare provider before taking nattokinase, particularly if they have existing cardiovascular conditions or are taking other medications.
Dosage and Administration
- Typical supplemental doses of nattokinase range from 2,000-4,000 FU (fibrinolytic units) daily, often taken in divided doses.
- However, the optimal dosage and administration of nattokinase for preventing thrombotic events is not well established, and further studies are needed to determine the most effective and safe dosage regimen.